WASHINGTON D.C. (September 30, 2022)

Pumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that it has launched Pumas-CP - a new clinical pharmacology platform for non-compartmental analysis (NCA), bioequivalence analysis, and pharmacokinetic and pharmacodynamic (PK/PD) modeling.

“Pharmacokineticists and clinical pharmacologists are looking for a simple tool to manage their workflows efficiently – loading data to TLFs and report creation with few clicks. Pumas-CP does just that!” said Dr. Joga Gobburu, CEO at Pumas-AI, and former U.S. Food and Drug Administration (FDA) Director, Division of Pharmacometrics. “Many pharmacologists spend too much time on repetitive tasks or dealing with software access burdens, and we have removed much of that from the process. As a former regulator, I’m proud to be part of an organization that helps get much-needed products to market faster.”

Developed by top industry scientists, Pumas-CP provides pharmacologists with these key benefits:

• Ease of use, with the ability to embed SOPs, customize TLFs, tailor reporting, and automate routine analyses and workflows,
• Validated, giving scientists the confidence to know that this platform has been welcomed with other software, and
• Global regulatory agencies, including US FDA, have accepted results directly from Pumas-CP outputs.

Co-founder and Chief Scientific Officer Vijay Ivaturi, Ph.D. added, “Scientists don’t have to be constrained by what current tools offer. Our vision is to simplify the workflows for NCA, BE and PK/PD modeling, such that routine tasks are handled in minutes. To that end, we are developing automated workflows for all standard animal and human PK studies. These workflows can be customized for each organization to lower the QC burden.”

Ask for a demo of Pumas-CP for desktop at sales@pumas.ai.

About Pumas-AI

Pumas-AI is a global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at Pumas-AI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development, pharmacometrics, front-end applications, and more. For additional information, visit www.pumasai.com

Media Contact

Don McLean, McLean Media 734-716-4182